Skip to content
Industry inflectionsBDXCSIQGLWTETFXTOYO

Medical Device and Solar Manufacturers See Company-Specific Tariff Relief Tied to US Investment

Editorial illustration for Medical Device and Solar Manufacturers See Company-Specific Tariff Relief Tied to US Investment
Published 5 min read

Summary

BD and TOYO say Section 232 tariff relief is granted company by company for US investment: BD pledged $19 billion, while TOYO's solar plan awaits approval.

Section 232 tariff relief is now being granted company by company in exchange for US manufacturing investment. Becton, Dickinson and Company (BDX), a medical device maker, and TOYO Co., Ltd (TOYO), a solar cell and module maker, described this on their earnings calls on November 5 and November 16, 2026, which shows the same approach moving from medical devices into solar [1][2].


How Section 232 relief now depends on a company's US investment plan

Section 232 is a provision of US trade law that lets the government impose tariffs or minimum import prices on imports on national security grounds. Medical devices, and polysilicon along with downstream solar products, now fall within its reach. Tariffs used to attach to the product and its country of origin, so importers of the same goods paid roughly the same duty. The Department of Commerce has now opened a second route: a company submits a US manufacturing investment plan, and if the plan is approved, Commerce may allow duty-free imports of production equipment and covered products in volumes it judges commensurate with the company's US investment [3]. What a company pays therefore depends not only on where it sources, but also on whether it holds an approved investment plan. TOYO's management said it does not expect the solar program to be radically different from what Commerce did for pharmaceuticals [2], so the same trade-off is being applied across industries.


BD has signed an agreement; TOYO's plan is still awaiting approval

On its fiscal fourth-quarter 2026 call, BD said it has committed to invest $19 billion in the US over several years, with $3 billion directed toward manufacturing expansion [1]. Management stressed that this is not incremental investment but a reprioritization of existing investment toward the US [1]. In return, BD's covered products and inputs would be relieved from future Section 232 tariffs, subject to the final scope of any future Section 232 actions and BD meeting agreed milestones [1]. Because neither scope nor timing is settled, the benefit is not included in BD's fiscal 2027 guidance [1].

On its November 16 call, TOYO said it has submitted an offset proposal to Commerce tied to its multi-year US investment plan, including a planned $357 million, 1.5-gigawatt HJT cell line (HJT is a high-efficiency solar cell technology) and a possible expansion into upstream solar products [2]. TOYO also said Commerce has not approved any plans yet, will probably not approve plans much before December 4, and expects approvals to continue through the first quarter of 2027 and beyond [2]. One company holds a conditional agreement and the other is still waiting, but the terms of the exchange are the same: US investment in return for tariff relief.


Why the tariff gap may accrue to companies holding approvals

Company-by-company approval creates two tariff costs within the same industry. A company with an approved plan can import cells, inputs or products duty-free, while an importer without one pays the full tariff. If selling prices move toward the higher, tariff-inclusive level, the difference stays with the plan holder, which then puts it into the US plants its plan promised. Solar pricing is already tiered by cell origin: T1 Energy (TE) said on its November 12 call that modules using imported cells are priced in the mid-30s cents per watt, while modules using US-made cells are priced in the mid-40s cents per watt [4].

The arrangement also favors larger companies. Teleflex (TFX), another medical device maker, said BD is a much different and much larger company, that it has no similar deal, and that it expects about $30 million of tariffs in 2026 and a similar amount in 2027 [5]. The limit of this analysis is that no company has quantified the benefit of relief, and no solar plan has been approved [1][2]. Points to track are which plans Commerce approves after December 4, how large the approved duty-free volumes are, and when BD adds the relief to its guidance.


Companies exposed to Section 232 offset plans

  • T1 Energy (TE): A US solar cell and module maker. In October it received a Commerce Section 232 waiver to import up to 1.725 gigawatts of solar cells for its Dallas plant, and it is applying for relief tied to its Austin cell plant investment, the same approval route TOYO is using [4].
  • Canadian Solar (CSIQ): Its US module plant in Mesquite relies on imported cells. In August management said Section 232 lets US manufacturing projects offset the duties and that it plans to apply, so the outcome bears directly on its cell import costs [6].
  • Corning (GLW): Makes wafers for the solar supply chain. Its third-quarter solar sales were $436 million, and management said Section 232 improves pricing and demand for its US-made solar products. Relief plans weight US upstream content, and T1's plan uses Corning wafers, so more approvals of such plans could lift demand for US-made wafers [7][4].

Sources

[1] Drillr · Becton, Dickinson and Company (BDX) · 2026-11-05 · Fiscal Q4 2026 earnings call

"The partnership also provides relief from future tariffs imposed under Section 232 on covered BD products and inputs, subject to the final scope and implementation of any future Section 232 actions and BD's achievement of agreed milestones."

[2] Drillr · TOYO Co., Ltd (TOYO) · 2026-11-16 · Q3 2026 earnings call

[3] Drillr · TOYO Co., Ltd (TOYO) · 2026-08-19 · Q2 2026 earnings call

[4] Drillr · T1 Energy (TE) · 2026-11-12 · Q3 2026 earnings call

[5] Drillr · Teleflex (TFX) · 2026-11-05 · Q3 2026 earnings call

[6] Drillr · Canadian Solar (CSIQ) · 2026-08-27 · Q2 2026 earnings call

[7] Drillr · Corning (GLW) · 2026-10-27 · Q3 2026 earnings call

This article only highlights industry changes and companies that may be overlooked. It is not a stock recommendation.

Want deeper analysis?

Ask drillr anything about BDX, CSIQ, GLW, TE, TFX, TOYO — powered by SEC filings, earnings calls, and real-time data.

Try drillr.ai for free

drillr can make mistakes. Information only — not investment advice. Learn more